Ewing Sarcoma — Trials

Ewing Sarcoma — Trials · CancerIndex

Clinical trials

Registered studies

217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 76
Recruiting: 41
Ph III recruiting: 1
Growth YoY: —
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (30)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05266196	A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)	unknown	Phase 1 / Phase 2	10	Salarius Pharmaceuticals, LLCINDUSTRY	1	Aug 1, 2023	clinicaltrials
NCT03359005	Irinotecan and Temozolomide for Ewing Sarcoma	unknown	Phase 2	60	Peking University People's HospitalOTHER	1	Nov 1, 2022	clinicaltrials